220 related articles for article (PubMed ID: 16109168)
1. In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine.
Howell G; West L; Jenkins C; Lineberry B; Yokum D; Rockhold R
BMC Pharmacol; 2005 Aug; 5():13. PubMed ID: 16109168
[TBL] [Abstract][Full Text] [Related]
2. The involvement of muscarinic receptor subtypes in the mediation of hypothermia, tremor, and salivation in male mice.
Sánchez C; Lembøl HL
Pharmacol Toxicol; 1994 Jan; 74(1):35-9. PubMed ID: 8159635
[TBL] [Abstract][Full Text] [Related]
3. Central and peripheral mediation of hypothermia, tremor and salivation induced by muscarinic agonists in mice.
Sánchez C; Meier E
Pharmacol Toxicol; 1993; 72(4-5):262-7. PubMed ID: 8372044
[TBL] [Abstract][Full Text] [Related]
4. Centrally active antimuscarinic analogs of oxotremorine selectively block physostigmine-induced hypertension, but not peripheral muscarinic vasodepression.
Vargas HM; Ringdahl B
J Pharmacol Exp Ther; 1990 Apr; 253(1):165-70. PubMed ID: 2329503
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects.
Kreutner W; Hey JA; Chiu P; Barnett A
Arzneimittelforschung; 2000 May; 50(5):441-8. PubMed ID: 10858871
[TBL] [Abstract][Full Text] [Related]
6. The effects of antihistamines with varying anticholinergic properties on voluntary and involuntary movement.
Naicker P; Anoopkumar-Dukie S; Grant GD; Kavanagh JJ
Clin Neurophysiol; 2013 Sep; 124(9):1840-5. PubMed ID: 23643576
[TBL] [Abstract][Full Text] [Related]
7. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle.
Cardelús I; Antón F; Beleta J; Palacios JM
Eur J Pharmacol; 1999 Jun; 374(2):249-54. PubMed ID: 10422766
[TBL] [Abstract][Full Text] [Related]
8. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport.
Liu H; Farley JM
BMC Pharmacol; 2005 Mar; 5():8. PubMed ID: 15790419
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects.
Kreutner W; Hey JA; Anthes J; Barnett A; Young S; Tozzi S
Arzneimittelforschung; 2000 Apr; 50(4):345-52. PubMed ID: 10800633
[TBL] [Abstract][Full Text] [Related]
10. Regional differences in receptor reserve for analogs of oxotremorine in vivo: implications for development of selective muscarinic agonists.
Ringdahl B; Roch M; Jenden DJ
J Pharmacol Exp Ther; 1987 Aug; 242(2):464-71. PubMed ID: 3612545
[TBL] [Abstract][Full Text] [Related]
11. The central and peripheral effectiveness of two oxotremorine-antagonists determined using oxotremorine-induced tremor and salivation.
Eicholzer A; Ogren SO
J Pharm Pharmacol; 1977 Oct; 29(10):609-11. PubMed ID: 21240
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic potentiation of muscarinic agonist evoked tremor and salivation in rat and mouse.
Ogren SO; Carlsson S; Bartfai T
Psychopharmacology (Berl); 1985; 86(3):258-64. PubMed ID: 3929296
[TBL] [Abstract][Full Text] [Related]
13. Nonmuscarinic neurotoxicity of oxotremorine.
Witkin JM; Alvarado-Garcia R; Lee MA; Witkin KM
J Pharmacol Exp Ther; 1987 Apr; 241(1):34-41. PubMed ID: 3572794
[TBL] [Abstract][Full Text] [Related]
14. Cholinergic M2 muscarinic receptor-mediated inhibition of endogenous noradrenaline release from the isolated vascularly perfused rat stomach.
Yokotani K; Osumi Y
J Pharmacol Exp Ther; 1993 Jan; 264(1):54-60. PubMed ID: 8423550
[TBL] [Abstract][Full Text] [Related]
15. Phenyl-substituted analogues of oxotremorine as muscarinic antagonists.
Nilsson BM; Vargas HM; Ringdahl B; Hacksell U
J Med Chem; 1992 Jan; 35(2):285-94. PubMed ID: 1732545
[TBL] [Abstract][Full Text] [Related]
16. Absence of anticholinergic activity of rolipram, an antidepressant with a novel mechanism of action, in three different animal models in vivo.
Wachtel H; Löschmann PA; Pietzuch P
Pharmacopsychiatry; 1988 Sep; 21(5):218-21. PubMed ID: 3227052
[TBL] [Abstract][Full Text] [Related]
17. Novel alkoxy-oxazolyl-tetrahydropyridine muscarinic cholinergic receptor antagonists.
Shannon HE; Bymaster FP; Hendrix JC; Quimby SJ; Mitch CH
Psychopharmacology (Berl); 1995 Jan; 117(2):208-15. PubMed ID: 7753969
[TBL] [Abstract][Full Text] [Related]
18. Differential response to cholinergic stimulation in psychogenitically selected rat lines.
Martin JR; Driscoll P; Gentsch C
Psychopharmacology (Berl); 1984; 83(3):262-7. PubMed ID: 6433388
[TBL] [Abstract][Full Text] [Related]
19. Meperidine does not block the cholinergic effects of oxotremorine.
Leander JD
Pharmacol Biochem Behav; 1979 Jun; 10(6):941-2. PubMed ID: 482317
[TBL] [Abstract][Full Text] [Related]
20. Alterations in behavioral responses to a cholinergic agonist in post-pubertal rats with neonatal ventral hippocampal lesions: relationship to changes in muscarinic receptor levels.
Laplante F; Nakagawasai O; Srivastava LK; Quirion R
Neuropsychopharmacology; 2005 Jun; 30(6):1076-87. PubMed ID: 15637638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
